Chantal Sauvageau completed her Doctorate in Medicine at Laval University in 1999, and obtained a Master’s degree in Community Health from the same University in 2002. She then completed her specialty training and obtained her certificate of specialist in Community Health from the Collège des médecins du Québec and the Royal College of Physicians and Surgeons of Canada, in 2004. She is a consultant in infectious diseases at the National Institute of Public Health of Quebec, and the Regional Directorate of Public Health of the national capital. She is a researcher in the Immunization Research Team of the Research Centre of the CHU de Québec, and an Associate Professor in the Faculty of Medicine at Laval University. She has been an active member of the Committee on Immunization of Quebec (CIQ) since 2008. She is also a member of the shingles working group as well as of the HPV working group of the National Advisory Committee on Immunization (NACI). In 2013, she participated in the work of the World Health Organization (WHO), leading to a WHO recommendation on the use of a 2-dose vaccination schedule for HPV vaccine.

Evaluate the impact of HPV vaccination and the vaccination against chickenpox and shingles

Her main research papers focus on HPV vaccination, particularly on the evaluation of the immunogenicity and efficacy of available vaccines, on the impact of varicella and shingles vaccination, on the training of healthcare professionals on immunization, and the problem of vaccine delays. More specifically, by conducting clinical trials, her projects aim to know the immune response to vaccines: duration of protection, decrease in antibody levels, impact of interactions and co-administration of vaccines on the immune response, effect of a booster dose, etc. Among other things, she is the co-principal investigator of a randomized clinical trial named ICI-HPV, having recruited 3,300 14-16 year old girls from 2013 to 2016, who are followed for 5 years. The trial aims to evaluate the effectiveness of a 2-dose schedule of HPV vaccination, 10 years after receiving the first dose of vaccine at an age of 9 or 10.

She also collaborates on projects related to the modeling and analysis of the cost-effectiveness of planned or implemented vaccination programs, as well as on studies related to the acceptability of implemented vaccination programs, by measuring the immunization coverage rate, as well as the perception of health professionals and of the population.

2400, avenue d'Estimauville
3e étage
U-3130
Québec, Québec
Canada G1E 7G9
130 entries « 1 of 13 »

Sauvageau C, Gilca V, Ouakki M, Kiely M, Coutlée F, Mathieu-Chartier S, Defay F, Lambert G

Sexual behavior, clinical outcomes and attendance of cervical cancer screening by HPV vaccinated and unvaccinated sexually active women.

Journal Article

Hum Vaccin Immunother, 2021.

Abstract | Links:

Carazo S, Talbot D, Boulianne N, Brisson M, Gilca R, Deceuninck G, Brousseau N, Drolet M, Ouakki M, Sauvageau C, Barkati S, Fortin É, Carignan A, De Wals P, Skowronski DM, De Serres G

Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada.

Journal Article

Clin Infect Dis, 2021.

Abstract | Links:

Gilca V, Sauvageau C, Amini R, Racine E

Vaccination des personnes immunosupprimées âgées de 18 à 49 ans et des adultes avec des maladies chroniques : vaccin sous-unitaire adjuvanté contre le zona (Zona-SU) : vaccin sous-unitaire adjuvanté contre le zona (Zona-SU)

Book

Institut national de santé publique du Québec, Montréal, QC, 2020, ISBN: 9782550879909.

Abstract | Links:

Kiely M, Bouchard F, Gilca V, Sicard N, Sauvageau C

COVID-19 (SARS-CoV-2): Recommandations intérimaires – Mesures à mettre en place pour les hôtels qui accueilleront des personnes en isolement volontaire ou obligatoire asymptomatiques) ou des personnes atteintes de COVID-19 ou sous investigation qui ne peuvent être isolées à la maison

Book

Institut national de santé publique du Québec, Montréal, Qc, 2020.

Abstract | Links:

Sauvageau C, Boucher F, Dionne M, Boulianne N, Gilca V, Brousseau N, Gilca R, Kiely M, De Serres G, De Wals P, Villeneuve J

Maintien des groupes ciblés dans le cadre du Programme d'immunisation contre l'influenza du Québec dans le contexte de la COVID-19. Avis du Comité sur l'immunisation du Québec

Book

Institut national de santé publique du Québec, Montréal, Québec, 2020.

Boucher F, De Serres G, Dionne M, Boulianne N, De Wals P, Gilca R, Gilca V, Brousseau N, Sauvageau C, Kiely M

Reprise des activités de vaccination en milieu scolaire dans le contexte de la COVID-19. Avis du Comité sur l'immunisation du Québec

Book

Institut national de santé publique du Québec, Montréal, Québec, 2020.

Beauregard M, Brousseau N, Ouakki M, Kiely M, Sauvageau C, Clement P, Guay M

Participation in an action research project on vaccine services for children: relationship with vaccine delays.

Journal Article

Hum Vaccin Immunother, 16 (12), 2020.

Abstract | Links:

Sauvageau C, Panicker G, Unger ER, De Serres G, Schiller J, Ouakki M, Gilca V

Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trials.

Journal Article

Hum Vaccin Immunother, 16 (3), 2020.

Abstract | Links:

Racine E, Gilca V, Amini R, Tunis M, Ismail S, Sauvageau C

A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients.

Journal Article

Vaccine, 38 (40), 2020.

Abstract | Links:

Kiely M, Boulianne N, Talbot D, Ouakki M, Guay M, Landry M, Sauvageau C, De Serres G

Children vaccination coverage surveys: Impact of multiple sources of information and multiple contact attempts.

Journal Article

Vaccine, 38 (5), 2020.

Abstract | Links:

130 entries « 1 of 13 »
Signaler des ajouts ou des modifications

Active projects

  • Évaluation de l'efficacité du programme québécois de vaccination contre le VPH : Étude de prévalence des types de VPH au Québec chez les garçons de 17 à 20 ans, from 2021-03-09 to 2022-05-31

Recently finished projects

  • ICI-VPH: IMpact des calendriers d'immunisation contre les VPH, from 2013-05-01 to 2021-03-31
  • Interchangeabilité des vaccins VPH., from 2011-03-29 to 2019-12-31
Data provided by the Université Laval research projects registery